Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing carbamazepine, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing carbamazepine are listed in tablet, capsule and suspension forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Carbamazepine is an anticonvulsant and mood stabilizer that compounding pharmacies prepare by prescription, including in topical pain creams.
Carbamazepine is an anticonvulsant that acts on voltage-gated sodium channels and reduces abnormal electrical activity in the brain. Tegretol suspension, tablets and XR tablets are FDA-approved for certain seizure types (partial seizures with complex symptomatology, generalized tonic-clonic seizures and mixed patterns) and for the pain of true trigeminal neuralgia; the label says it is not a simple analgesic for trivial aches or pains. Equetro extended-release capsules are also approved for acute manic or mixed episodes of bipolar I disorder. A 2020 National Academies review of compounded topical pain creams lists carbamazepine among the ingredients used in some of these creams; topical use is not an FDA-approved indication. A prescriber might also order carbamazepine compounded for a strength or dosage form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Carbamazepine carries boxed warnings for serious and sometimes fatal skin reactions, including toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), strongly associated with the HLA-B*1502 allele, found almost only in people with Asian ancestry. At-risk patients should be screened before starting, and those who test positive should not take it unless the benefit clearly outweighs the risk. A second boxed warning covers aplastic anemia and agranulocytosis. Do not use it with a history of bone marrow depression, sensitivity to carbamazepine or tricyclic compounds, or with nefazodone; the label says to stop MAO inhibitors at least 14 days before starting. Other warnings include DRESS, other hypersensitivity reactions and suicidal thoughts. MedlinePlus says it may make hormonal birth control less reliable. The label says it can cause fetal harm, including spina bifida. LactMed says it is not a reason to stop breastfeeding. Talk to your prescriber or pharmacist about side effects.
StatPearls describes carbamazepine binding voltage-gated sodium channels and holding them in the inactivated state, reducing action potential generation; the Tegretol label describes reduced polysynaptic responses and blocked post-tetanic potentiation. It is 76% bound to plasma proteins. Peak levels occur about 1.5 hours after suspension, 4 to 5 hours after conventional tablets and 3 to 12 hours after XR tablets. Carbamazepine induces its own metabolism: initial half-life of 25 to 65 hours falls to 12 to 17 hours with repeated dosing, and autoinduction completes after 3 to 5 weeks of fixed dosing. CYP3A4 is the major isoform forming carbamazepine-10,11-epoxide, an active metabolite; CYP3A4 inhibitors raise carbamazepine levels. Labeled indications: Tegretol for epilepsy (absence seizures do not appear to respond) and trigeminal neuralgia; Equetro also for acute manic or mixed episodes in bipolar I disorder. Dosing is per prescriber. The label recommends HLA-B*1502 typing in genetically at-risk patients, complete pretreatment blood counts including platelets, and close monitoring of carbamazepine levels when interacting drugs are started or stopped. It also notes an association between HLA-A*3101 and hypersensitivity reactions in some populations.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally
